AbbVie Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), GoodRx Holdings (GDRX) and Organon (OGN)
TD Cowen Adjusts Price Target on AbbVie to $195 From $180
AbbVie Analyst Ratings
Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Roche Holding AG (OtherRHHVF) and UnitedHealth (UNH)
Redburn Atlantic Adjusts Price Target on AbbVie to $203 From $207
Analysts' Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX) and AbbVie (ABBV)
AbbVie (ABBV) Gets a Buy From Barclays
AbbVie Analyst Ratings
AbbVie (ABBV) Receives a Buy From Cantor Fitzgerald
AbbVie Analyst Ratings
Buy Rating Affirmed for AbbVie on Strong Aesthetics Market Position and Positive Sales Outlook
AbbVie Analyst Ratings
AbbVie Analyst Ratings
Strong Financial Outlook and Strategic Initiatives Underpin Buy Rating for AbbVie
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)
AbbVie Analyst Ratings
Buy Rating Affirmed: AbbVie's Promising Growth Trajectory and Financial Outlook
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)